Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.39 |
| ▸ | ITGAV | P06756 | 3/20 | 0.39 |
| ▸ | AR | P10275 | 4/20 | 0.38 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL186078 | 0.91 | LRRK2 (0.40) | TAS2R14FFAR1FFAR4LRRK2ITGB3 | |
| SCHEMBL185390 | 0.89 | LRRK2 (0.47) | FFAR1FFAR4LRRK2BRD4BPTF | |
| Trifluoroacetic Acid SCHEMBL185638 | 0.84 | TAS2R14 (0.46) | TAS2R14ITGB3ITGB1ITGA5ITGAV | |
| SCHEMBL2806814 | 0.80 | LRRK2 (0.42) | TAS2R14FFAR1FFAR4LRRK2NAMPT | |
| SCHEMBL27853555 | 0.79 | LRRK2 (0.46) | LRRK2BRD4BPTFKAT2B | |
| Trifluoroacetic Acid SCHEMBL185218 | 0.78 | ACACB (0.46) | TAS2R14FFAR1FFAR4ITGB3ITGB1 | |
| Trifluoroacetic Acid SCHEMBL185630 | 0.78 | LRRK2 (0.40) | TAS2R14LRRK2ITGB3ITGB1ITGA5 | |
| Trifluoroacetic Acid SCHEMBL185394 | 0.78 | CXCR2 (0.40) | TAS2R14FFAR1LRRK2ITGB3ITGB1 | |
| SCHEMBL20552693 | 0.74 | LRRK2 (0.51) | TAS2R14LRRK2ARMPO | |
| SCHEMBL2805481 | 0.74 | AKT2 (0.39) | LRRK2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-05-23 | — | — | US | disclosed |
| EP-2401256-B1 | Compounds as bradykinin B1 antagonists | BOEHRINGER INGELHEIM INT (DE) | 2013-04-17 | — | — | EP | disclosed |
| EP-2401256-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20100240669-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-23 | — | — | US | disclosed |
| WO-2010097372-A1 | COMPOUNDS AS BRADYKININ B1 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131075-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | TAS2R14 477/4885FFAR1 532/4885FFAR4 1544/4885 |
| US-20100240669-A1 | NEW COMPOUNDS | ADORA1, H1-10, P2RY11 | TAS2R14 477/4885FFAR1 532/4885FFAR4 1544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.